16.3 Obstetric Emergencies: Preeclampsia, Hemorrhage & Amniotic Fluid Embolism

16.3 Obstetric Emergencies: Preeclampsia, Hemorrhage & Amniotic Fluid Embolism

Obstetric emergencies develop with breathtaking speed and carry substantial risks of maternal and neonatal morbidity and mortality. The nurse anesthetist must maintain mastery over hypertensive disorders of pregnancy, the pharmacology of magnesium sulfate, the differential diagnosis of catastrophic peripartum hemorrhage, and the resuscitation of amniotic fluid embolism.

---

1. Preeclampsia, Severe Features & HELLP Syndrome

Preeclampsia affects $5 - 8%$ of all pregnancies. Its root etiology is abnormal trophoblastic invasion of the maternal spiral arteries, leaving them as narrow, high-resistance, muscular vessels. The resulting placental ischemia triggers the systemic release of anti-angiogenic factors (such as soluble fms-like tyrosine kinase-1 [sFlt-1] and soluble endoglin [sEng]), provoking widespread maternal vascular endothelial dysfunction, intense vasospasm, microvascular thrombosis, increased capillary permeability, and end-organ hypoperfusion.

+---------------------------------------------------------------------------------------------------------+
|                                 PREECLAMPSIA SEVERE FEATURES CRITERIA                                   |
+----------------------------+----------------------------------------------------------------------------+
| Organ System / Domain      | Diagnostic Criteria for Severe Features (Any 1 elevates to Severe)        |
+----------------------------+----------------------------------------------------------------------------+
| **Blood Pressure**         | • Systolic BP $\ge 160 \text{ mmHg}$ OR Diastolic BP $\ge 110 \text{ mmHg}$   |
|                            |   on 2 occasions at least 4 hours apart (or verified in minutes for tx)   |
+----------------------------+----------------------------------------------------------------------------+
| **Thrombocytopenia**       | • Platelet count $< 100,000 /\text{mm}^3$                                  |
+----------------------------+----------------------------------------------------------------------------+
| **Renal Insufficiency**    | • Serum Creatinine $> 1.1 \text{ mg/dL}$ (or doubling of baseline          |
|                            |   in the absence of underlying renal disease)                              |
+----------------------------+----------------------------------------------------------------------------+
| **Hepatic Impairment**     | • Serum transaminases (AST, ALT) $> 2\times$ upper limit of normal         |
|                            | • Severe, persistent epigastric or right upper quadrant pain               |
+----------------------------+----------------------------------------------------------------------------+
| **Pulmonary System**       | • **Pulmonary Edema** (dyspnea, orthopnea, hypoxemia, rales)               |
+----------------------------+----------------------------------------------------------------------------+
| **Cerebral / Visual**      | • New-onset headache unresponsive to medication, photopsia, scotomata,      |
|                            |   cortical blindness, hyperreflexia with clonus                            |
+----------------------------+----------------------------------------------------------------------------+

HELLP Syndrome

HELLP syndrome develops in $10 - 20%$ of women with severe preeclampsia and represents an acute microangiopathic hemolytic process:

• H (Hemolysis): Microangiopathic hemolytic anemia with fragmented RBCs (schistocytes) on peripheral blood smear, elevated total bilirubin ($\ge 1.2 \text{ mg/dL}$), low haptoglobin, and markedly elevated LDH ($> 600 \text{ IU/L}$).
• EL (Elevated Liver Enzymes): AST and ALT $\ge 2\times$ upper limit of normal.
• LP (Low Platelets): Platelet count $< 100,000 /\text{mm}^3$. Patients are at risk for subcapsular hepatic hematoma and catastrophic hepatic rupture.

Acute Antihypertensive Pharmacotherapy

The goal of antihypertensive therapy in preeclampsia is to reduce maternal blood pressure to a safe range ($140 - 150 / 90 - 100 \text{ mmHg}$) to prevent hemorrhagic stroke and placental abruption while avoiding excessive hypotension that would compromise uteroplacental perfusion.

• Labetalol: Combined $\alpha_1$ and non-selective $\beta$-blocker ($1:7$ ratio IV). Initial dose: $20 \text{ mg}$ IV, followed by $40 - 80 \text{ mg}$ every $10 - 20 \text{ minutes}$ (maximum cumulative dose: $300 \text{ mg}$), or continuous infusion at $1 - 2 \text{ mg/min}$. Avoid in asthma, severe bradycardia, or uncompensated heart failure.
• Hydralazine: Direct arteriolar vasodilator. Initial dose: $5 - 10 \text{ mg}$ IV every $20 \text{ minutes}$ (maximum dose: $20 - 30 \text{ mg}$). Can cause reflex tachycardia and headache.
• Nicardipine: Dihydropyridine calcium channel blocker. Initial infusion: $5 \text{ mg/hr}$ IV, titrated by $2.5 \text{ mg/hr}$ every $5 - 15 \text{ minutes}$ (maximum: $15 \text{ mg/hr}$). Highly titratable and effective.

---

2. Magnesium Sulfate: Pharmacology, Toxicity & Drug Interactions

Magnesium sulfate ($MgSO_4$) is the anticonvulsant of choice for the prevention and treatment of eclamptic seizures (superior to phenytoin, diazepam, and nimodipine). Magnesium acts by:

1. Competing with calcium at presynaptic voltage-gated calcium channels, decreasing acetylcholine (ACh) release at the neuromuscular junction.
2. Acting as a central NMDA receptor antagonist, suppressing neuronal hyperexcitability.
3. Inducing cerebral and peripheral vasodilation, relieving cerebral vasospasm and reducing blood-brain barrier permeability.

+---------------------------------------------------------------------------------------------------------+
|                               MAGNESIUM SULFATE CLINICAL & TOXICITY SPECTRUM                            |
+-------------------------+-------------------------+-----------------------------------------------------+
| Serum Mg²⁺ Level (mEq/L)| Serum Mg²⁺ (mg/dL)      | Clinical Manifestations & Physiological Effects     |
+-------------------------+-------------------------+-----------------------------------------------------+
| **1.5 – 2.5 mEq/L**     | 1.8 – 3.0 mg/dL         | • Normal baseline physiological level               |
+-------------------------+-------------------------+-----------------------------------------------------+
| **4.0 – 7.0 mEq/L**     | **4.8 – 8.4 mg/dL**     | • **Therapeutic Range for Eclampsia Seizure Proph.**|
|                         | (2.0 – 3.5 mmol/L)      | • Mild ECG changes (PQ prolongation), mild sedation |
+-------------------------+-------------------------+-----------------------------------------------------+
| **8.0 – 10.0 mEq/L**    | 9.6 – 12.0 mg/dL        | • **LOSS OF DEEP TENDON REFLEXES (PATELLAR / DTRs)**|
|                         |                         | • First objective clinical sign of impending tox!  |
+-------------------------+-------------------------+-----------------------------------------------------+
| **10.0 – 12.0 mEq/L**   | 12.0 – 14.4 mg/dL       | • **RESPIRATORY DEPRESSION & APNEA**                |
|                         |                         | • SA and AV nodal heart block, QRS widening         |
+-------------------------+-------------------------+-----------------------------------------------------+
| **> 12.0 – 15.0 mEq/L** | > 14.4 – 18.0 mg/dL     | • **CARDIAC ARREST (ASYSTOLE / VFIB)**              |
|                         |                         | • Complete flaccid quadriplegia                     |
+-------------------------+-------------------------+-----------------------------------------------------+

                      [MAGNESIUM TOXICITY HIERARCHY & PROGRESSION]

      Serum Mg2+ (mEq/L)
        >12 mEq/L | -----------------------------------------> **CARDIAC ARREST (Asystole)**
                  |
        10-12     | -----------------------------------------> **RESPIRATORY ARREST & AV Block**
                  |
        8-10      | -----------------------------------------> **LOSS OF PATELLAR DTRs** (Check 1st!)
                  |
        4-7       | =========================================> **THERAPEUTIC WINDOW** (Seizure Proph)
                  |
        1.5-2.5   | -----------------------------------------> Normal Baseline

Magnesium Administration & Antidote Protocol

• Dosing Regimen: Loading dose of $4 - 6 \text{ g}$ IV over $15 - 20 \text{ minutes}$, followed by a continuous maintenance infusion of $1 - 2 \text{ g/hr}$ for $24 \text{ hours}$ postpartum. Magnesium is cleared $100%$ renally; in parturients with renal impairment ($Cr > 1.1 \text{ mg/dL}$ or oliguria $<30 \text{ mL/hr}$), the maintenance infusion must be reduced or withheld while frequently checking serum levels.
• Antidote for Toxicity:
  1. Immediately stop the $MgSO_4$ infusion.
  2. Administer Calcium Gluconate $1 \text{ g}$ IV ($10 \text{ mL}$ of $10%$ solution) slowly over $3 - 5 \text{ minutes}$ (or Calcium Chloride $300 - 500 \text{ mg}$ IV via central access). Calcium directly antagonizes magnesium at both the neuromuscular junction and cardiac conducting membranes.
  3. Support airway and ventilation with $100% \text{ O}_2$; perform endotracheal intubation if the patient is apneic.

Anesthetic Interaction with Neuromuscular Blockers

Magnesium markedly potentiates both depolarizing and non-depolarizing neuromuscular blocking agents (NMBAs):

• Non-depolarizing NMBAs (Rocuronium, Vecuronium, Cisatracurium): Magnesium reduces presynaptic ACh release and stabilizes the postjunctional motor endplate. The potency and clinical duration of action of non-depolarizers can be increased by 200% to 400%. Doses must be reduced by $50 - 75%$, and quantitative train-of-four (TOF) monitoring is mandatory.
• Depolarizing NMBAs (Succinylcholine): Succinylcholine duration may be prolonged due to competitive membrane stabilization. However, standard intubating doses ($1.0 - 1.5 \text{ mg/kg}$) should NOT be reduced for RSI to ensure rapid, reliable intubating conditions.

Neuraxial Platelet Safety Thresholds in Preeclampsia

Neuraxial anesthesia (early labor epidural / spinal for C-section) is the preferred anesthetic modality in preeclampsia because it avoids the dangerous hypertensive surges and airway hazards associated with general endotracheal intubation.

• Platelet Count $\ge 70,000 - 80,000 /\text{mm}^3$: Neuraxial placement (and catheter removal) is considered safe according to SOAP/ASRA consensus guidelines, provided the platelet count is stable (not precipitously falling), coagulation studies (PT/INR, aPTT, fibrinogen) are normal, and there is no concurrent anticoagulant therapy.
• Platelet Count $50,000 - 70,000 /\text{mm}^3$: Individualized risk-benefit decision based on trend of platelet decline, presence of platelet dysfunction, viscoelastic testing (TEG/ROTEM Maximum Clot Firmness), and airway difficulty assessment.
• Platelet Count $< 50,000 /\text{mm}^3$: Neuraxial anesthesia is contraindicated due to unacceptable risk of spinal-epidural hematoma.

---

3. Third-Trimester Obstetric Hemorrhage

Obstetric hemorrhage remains a leading cause of maternal mortality worldwide. Rapid clinical discrimination among the major causes is essential.

+---------------------------------------------------------------------------------------------------------+
|                               THIRD-TRIMESTER HEMORRHAGE DIFFERENTIAL MATRIX                            |
+------------------+------------------------------+---------------------------+---------------------------+
| Condition        | Clinical Presentation        | Pathophysiology           | Anesthetic & Obstetric    |
|                  | & Bleeding Characteristics   | & Mechanism               | Management                |
+------------------+------------------------------+---------------------------+---------------------------+
| **Placenta       | • **Painless, bright red**   | • Placenta implants over  | • **NO DIGITAL VAGINAL**  |
|   Previa**       |   vaginal bleeding           |   or near internal os     |   **EXAM!** (avoids tear) |
|                  | • Soft, non-tender uterus    | • Tearing of placental    | • Elective Cesarean delivery|
|                  | • Normal fetal heart rate    |   attachments as lower    | • Fluid resuscitation;    |
|                  |   until maternal shock       |   uterine segment thins   |   type & crossmatch       |
+------------------+------------------------------+---------------------------+---------------------------+
| **Placental      | • **Painful, dark red**      | • Premature detachment of | • **Massive release of    |
|   Abruption**    |   vaginal bleeding (or 20%   |   normally implanted      |   decidual Tissue Factor  |
|   *(Abruptio)*   |   concealed behind placenta) |   placenta from myometrium|   causes **Consumptive**  |
|                  | • **Hypertonic/woody,**      | • Retroplacental hematoma |   **DIC** & hypofibrinogen|
|                  |   **severely tender uterus** |   expands under pressure  | • Emergent C-section; MTP;|
|                  | • Severe fetal distress      | • Maternal HTN is #1 risk |   platelets & cryo target |
+------------------+------------------------------+---------------------------+---------------------------+
| **Placenta       | • Massive, torrential        | • Defective decidua       | • Multidisciplinary team; |
|   Accreta        |   bleeding upon attempted    |   basalis allows chorionic|   arterial line, 2 large- |
|   Spectrum (PAS)**|  manual placental removal   |   villi to invade uterine |   bore IVs, Level 1 infuser|
|                  | • Visible invasive vascularity|  wall (Accreta: surface; | • Massive Transfusion (MTP)|
|                  |   on ultrasound / MRI        |   Increta: deep muscle;   | • Planned Cesarean        |
|                  |                              |   Percreta: through serosa|   Hysterectomy; Cell Saver|
+------------------+------------------------------+---------------------------+---------------------------+
| **Uterine        | • Sudden tearing abd. pain   | • Complete disruption of  | • Emergent exploratory    |
|   Rupture**      | • Loss of fetal station      |   all uterine wall layers |   laparotomy; fetal extrac|
|                  | • Cessation of contractions  | • #1 risk: Prior classic  | • Massive fluid resuscit. |
|                  | • Sudden maternal shock      |   (vertical) C/S scar     | • Uterine repair vs hyst. |
+------------------+------------------------------+---------------------------+---------------------------+

                       [PLACENTA ACCRETA SPECTRUM (PAS) DEPTH]

         Normal Decidua         **ACCRETA (~75%)**         **INCRETA (~15%)**         **PERCRETA (~10%)**
        ================      ====================      ====================      ====================
          [ Placenta ]            [ Placenta ]              [ Placenta ]              [ Placenta ]
        ----------------      --------------------      --------------------      --------------------
        [Decidua Basalis]     (No Decidua Layer)        (No Decidua Layer)        (No Decidua Layer)
        ----------------      --------------------      --------------------      --------------------
        [  Myometrium  ]      [Attaches to Myomet]      [Invades into Myomet]     [Penetrates THROUGH]
        ----------------      --------------------      --------------------      --------------------
        [Uterine Serosa]      [  Uterine Serosa  ]      [  Uterine Serosa  ]      >>> Invades Bladder/
                                                                                  >>> Pelvic Viscera

---

4. Amniotic Fluid Embolism (AFE) & The A-OK Protocol

Amniotic Fluid Embolism (also termed Anaphylactoid Syndrome of Pregnancy) occurs in $1:40,000$ deliveries and is characterized by entry of amniotic fluid, fetal cells, and procoagulants into the maternal venous circulation.

Biphasic Pathophysiology

1. Phase 1 (Acute Pulmonary Vasospasm & Right Heart Failure - First 30 Minutes):
   • Amniotic fluid elements trigger massive release of endogenous vasoactive mediators (thromboxane A2, endothelin, serotonin).
   • Intense pulmonary vasoconstriction causes acute pulmonary hypertension, acute right ventricular failure (cor pulmonale), severe ventilation-perfusion mismatch with right-to-left shunting, profound hypoxemia, and sudden cardiovascular collapse / cardiac arrest.
2. Phase 2 (Left Heart Failure & Consumptive Coagulopathy):
   • Surviving patients transition into left ventricular failure, cardiogenic shock, and non-cardiogenic pulmonary edema (capillary leak).
   • Procoagulants in amniotic fluid trigger widespread consumptive coagulopathy / Disseminated Intravascular Coagulation (DIC) with explosive hyperfibrinolysis within minutes, manifesting as massive hemorrhage from all mucosal surfaces and puncture sites.

                       [BIPHASIC PATHOPHYSIOLOGY OF AFE]

               [Entry of Amniotic Fluid / Fetal Antigens into Maternal Blood]
                                      |
                                      v
                 ===========================================
                 >>> PHASE 1: ACUTE RV PULMONARY PHASE <<<
                 ===========================================
                 • Intense Pulmonary Vasoconstriction
                 • Acute Cor Pulmonale (RV Failure & Dilation)
                 • Profound Hypoxemia ($V/Q$ Shunting) & Shock / Arrest
                                      |
                                      v
                 ===========================================
                 >>> PHASE 2: LV FAILURE & CONSUMPTIVE DIC <<<
                 ===========================================
                 • Left Ventricular Dysfunction & Flash Pulmonary Edema
                 • Massive Consumption of Fibrinogen & Platelets
                 • Fulminant DIC with Torrential Bleeding

Resuscitation & The Evidence-Based "A-OK" Protocol

• Immediate ACLS & Airway: Intubate with $100% \text{ O}_2$, institute high-quality chest compressions with continuous $15^\circ$ left uterine displacement.
• Perimortem Cesarean Delivery (Resuscitative Hysterotomy): If maternal cardiac arrest occurs and spontaneous circulation (ROSC) is not achieved within 4 minutes, initiate emergent Cesarean delivery immediately at the bedside, aiming for complete fetal delivery within 5 minutes. Evacuation of the gravid uterus eliminates aortocaval compression, improves venous return, and restores thoracic compliance, dramatically improving maternal resuscitation success.
• The "A-OK" Pharmacologic Protocol:
  1. Atropine ($0.8 - 1.0 \text{ mg}$ IV): Blocks vagally mediated cardiopulmonary reflexes, severe bradycardia, and vagal pulmonary vasospasm.
  2. Ondansetron ($8 \text{ mg}$ IV): A selective $5-HT_3$ receptor antagonist; blocks serotonin release from activated, degranulating platelets, thereby blunting serotonin-induced pulmonary vasoconstriction and right heart failure.
  3. Ketorolac ($30 \text{ mg}$ IV): Cyclooxygenase (COX) inhibitor; blocks the production of thromboxane A2 and vasoconstrictive prostaglandins from the arachidonic acid cascade.
• Coagulopathy Management: Activate Massive Transfusion Protocol (MTP $1:1:1$). Administer Cryoprecipitate ($10 - 20 \text{ units}$) or Fibrinogen Concentrate to maintain fibrinogen $>200 \text{ mg/dL}$. Administer Tranexamic Acid ($1 \text{ g}$ IV) to inhibit hyperfibrinolysis.